Latest Manufacturing Scalability News

Papyrus Australia updates its timeline for delivering biodegradable fibre board to TBS Mining Solutions, following trial results that require product refinements. Commercial supply is now expected from November 2026, with acceptance testing due by September.

ClearVue Technologies has developed a unique manufacturing capability allowing its Gen 3 Vision Glass to have soft high-performance Low-E coatings applied on surface 4, the optimal position for solar heat control, after photovoltaic cells are laminated. This breakthrough enhances thermal performance and expands commercial façade market access globally.

Papyrus Australia has tapped related party L39 Capital to lead a capital raise and secured an interest-bearing $200,000 loan from Irwin Biotech, with conversion into shares and options pending shareholder approval.

Papyrus Australia reached a key production milestone by delivering 200 biodegradable Collar Keeper® samples to TBS Mining Solutions, confirming its manufacturing scalability. The company’s May cash flow shows a steady funding runway amid ongoing R&D and commercialisation efforts.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

Optiscan Imaging has submitted its FDA dossier for InSpecta®, marking a crucial step toward US veterinary market entry, while progressing clinical studies for InVue® and InForm® ahead of further FDA submissions in 2026.

Cleo Diagnostics (ASX:COV) has hit a major milestone by completing sample collection for its pivotal U.S. ovarian cancer trial, while progressing manufacturing and analytical validation steps toward FDA 510(k) submission.

Synertec Corporation Limited reported a 20% increase in revenue to $10.2 million for the half-year ended 31 December 2025, alongside a 40% improvement in net loss after tax. The company’s Powerhouse renewable energy system continues to gain traction, supported by strategic partnerships and expanded manufacturing.

INOVIQ Limited has reported compelling preclinical results for its CAR-NK-exosome therapy targeting triple-negative breast cancer, showing significant tumor reduction and perfect survival in treated mice.

Archer Materials has partnered with Belgium’s IMEC to develop a scalable, cost-effective potassium ion biosensor using silicon semiconductor technology, aiming to accelerate commercial production by late 2025.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

INOVIQ's December quarterly update reveals significant progress in its cancer diagnostic and therapeutic programs, including a highly accurate ovarian cancer screening test and promising breast cancer therapeutics, supported by growing EXO-NET customer adoption and a solid cash position.